Allergy Therapeutics (AGY) — Working Capital to Net Assets Ratio

Latest as of June 2025: -26.5%

Allergy Therapeutics (AGY) has a Working Capital to Net Assets ratio of -26.5% as of June 2025. Working capital of GBX7.49 Million (current assets of GBX34.68 Million minus current liabilities of GBX27.19 Million) is measured against net assets of GBX-28.19 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See AGY net asset quality index to measure how much of total assets are equity-financed.

WC/NA Ratio

-26.5%
Working Capital / Net Assets

Working Capital

GBX7.49 Million
GBX

Current Assets

GBX34.68 Million
GBX

Current Liabilities

GBX27.19 Million
GBX

Allergy Therapeutics Working Capital to Net Assets (2002–2025)

This chart shows how Allergy Therapeutics's Working Capital to Net Assets ratio has evolved across 24 annual periods from 2002 to 2025. As of June 2025, the ratio stands at -26.5%, reflecting working capital of GBX7.49 Million against net assets of GBX-28.19 Million GBX. Check AGY goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Annual Working Capital to Net Assets for Allergy Therapeutics (2002–2025)

The table below presents the year-by-year Working Capital to Net Assets ratio for Allergy Therapeutics from 2002 to 2025, covering 24 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Allergy Therapeutics (AGY) total market value.

Year WC/NA Ratio Working Capital (GBX) Net Assets Current Assets Current Liabilities Change (pp)
2025 -26.5% GBX7.49 Million GBX-28.19 Million GBX34.68 Million GBX27.19 Million ▼ -375.3 pp
2024 348.8% GBX12.94 Million GBX3.71 Million GBX33.48 Million GBX20.55 Million ▼ -375.4 pp
2023 724.2% GBX14.96 Million GBX2.07 Million GBX33.53 Million GBX18.57 Million ▲ +659.7 pp
2022 64.5% GBX24.34 Million GBX37.77 Million GBX42.39 Million GBX18.05 Million ▼ -17.2 pp
2021 81.6% GBX39.63 Million GBX48.53 Million GBX57.86 Million GBX18.23 Million ▼ -2.7 pp
2020 84.4% GBX36.94 Million GBX43.78 Million GBX55.17 Million GBX18.23 Million ▲ +5.1 pp
2019 79.3% GBX29.77 Million GBX37.56 Million GBX46.62 Million GBX16.86 Million ▲ +8.5 pp
2018 70.8% GBX16.30 Million GBX23.03 Million GBX30.93 Million GBX14.63 Million ▼ -7.5 pp
2017 78.2% GBX23.44 Million GBX29.96 Million GBX37.46 Million GBX14.02 Million ▼ -4.5 pp
2016 82.7% GBX25.09 Million GBX30.32 Million GBX37.61 Million GBX12.52 Million ▲ +6.2 pp
2015 76.5% GBX26.37 Million GBX34.47 Million GBX33.79 Million GBX7.42 Million ▲ +25.2 pp
2014 51.3% GBX7.74 Million GBX15.07 Million GBX14.21 Million GBX6.47 Million ▲ +4.7 pp
2013 46.6% GBX6.84 Million GBX14.67 Million GBX14.46 Million GBX7.62 Million ▲ +10.4 pp
2012 36.2% GBX5.29 Million GBX14.59 Million GBX13.03 Million GBX7.75 Million ▼ -139.9 pp
2011 176.1% GBX3.77 Million GBX2.14 Million GBX14.91 Million GBX11.15 Million ▲ +52.1 pp
2010 124.0% GBX4.82 Million GBX3.89 Million GBX14.80 Million GBX9.98 Million ▲ +70.8 pp
2009 53.2% GBX-12.33 Million GBX-23.18 Million GBX9.44 Million GBX21.77 Million ▲ +81.7 pp
2008 -28.4% GBX3.21 Million GBX-11.29 Million GBX11.32 Million GBX8.11 Million ▼ -65.4 pp
2007 37.0% GBX3.18 Million GBX8.60 Million GBX14.04 Million GBX10.86 Million ▼ -43.0 pp
2006 80.0% GBX26.15 Million GBX32.70 Million GBX31.09 Million GBX4.94 Million ▲ +6.0 pp
2005 74.0% GBX14.86 Million GBX20.08 Million GBX20.98 Million GBX6.12 Million ▲ +41.6 pp
2004 32.4% GBX2.29 Million GBX7.08 Million GBX5.57 Million GBX3.28 Million ▲ +5.3 pp
2003 27.0% GBX1.50 Million GBX5.55 Million GBX5.50 Million GBX4.00 Million ▲ +3.9 pp
2002 23.1% GBX-1.02 Million GBX-4.40 Million GBX3.58 Million GBX4.59 Million
pp = percentage points